Clinical Trial

Disease: Transfusion-dependent Beta-thalassemia, TDT, (NCT06298630)

Disease info:

Beta-thalassemia is a group of blood disorders characterised by a reduction in the production of haemoglobin. Haemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

Haemoglobin is encoded by genes that encode the building blocks of the haemoglobin protein. Mutations in these genes can produce abnormal haemoglobins leading to a family of conditions termed "haemoglobinopathies". Abnormal haemoglobin appears in one of three basic circumstances:

Structural defects in the haemoglobin molecule. Alterations in the gene for one of the two haemoglobin subunit chains, alpha (a) or beta (b), are called mutations. Often, mutations change a single amino acid building block in the subunit. Most commonly the change is innocuous, perturbing neither the structure nor function of the haemoglobin molecule. Occasionally, alteration of a single amino acid dramatically disturbs the behavior of the haemoglobin molecule and produces a disease state. Sickle haemoglobin exemplifies this phenomenon.
Diminished production of one of the two subunits of the haemoglobin molecule. Mutations that produce this condition are termed "thalassemias." Equal numbers of haemoglobin alpha and beta chains are necessary for normal function. Haemoglobin chain imbalance damages and destroys red cells thereby producing anaemia. Although there is a dearth of the affected haemoglobin subunit, with most thalassemias the few subunits synthesised are structurally normal.
Abnormal associations of otherwise normal subunits. A single subunit of the alpha chain (from the a-globin locus) and a single subunit from the b-globin locus combine to produce a normal haemoglobin dimer. With severe a-thalassemia, the b-globin subunits begin to associate into groups of four (tetramers) due to the paucity of potential a-chain partners. These tetramers of b-globin subunits are functionally inactive and do not transport oxygen. No comparable tetramers of alpha globin subunits form with severe beta-thalassemia. Alpha subunits are rapidly degraded in the absence of a partner from the beta-globin gene cluster (gamma, delta, beta globin subunits).
In individuals suffering from beta-thalassemia, low levels of haemoglobin lead to a lack of oxygen in many parts of the body. People with beta-thalassemia are at an increased risk of developing abnormal blood clots.

Beta thalassemia is classified into two types depending on symptom severity. Transfusion-dependent thalassemia, also known as thalassemia major, is the more severe, while thalassemia intermedia is less severe.

Annually, approximately 1 in 100,000 cases are diagnosed worldwide. Beta-thalassaemia occurs most frequently in people from Mediterranean countries, North Africa, the Middle East, India, China and South East Asia.
Official title:
Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia


Name: Xiaochen Wang, phD

Phone: 021-64340008



First Affiliated Hospital of Guangxi Medical University
Xiangya Hospital of Central South University
Chinese Academy of Medical Sciences
Nanfang Hospital, Southern Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Shenzhen Children 's Hospital


China, Guangxi

The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY, Guangxi, China, 530021

China, Guangdong

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, 510006

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China, 510006

Shenzhen Children 's Hospital, Shenzhen, Guangdong, China, 510006

China, Guangxi

No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital, Nanning, Guangxi, China, 530021

China, Hunan

Xiangya Hospital of Central South University, Changsha, Hunan, China, 510510

China, Tianjin

Tianjin Institute of Hematology, Tianjin, Tianjin, China, 300000

Study start:
Dec. 8, 2024
45 participants
Gene editing method:
Type of edit:
Gene disruption
Delivery method:
- Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active not recruiting


To observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Last updated: Apr. 17, 2024
Search CRISPR Medicine